Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Drop in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 1,948 shares, a decrease of 89.5% from the May 14th total of 18,505 shares. Based on an average trading volume of 324,828 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Provectus Biopharmaceuticals Stock Performance

Shares of PVCT traded down $0.00 during mid-day trading on Thursday, hitting $0.07. 17,000 shares of the company traded hands, compared to its average volume of 266,222. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.11. The business has a 50 day moving average of $0.06 and a 200 day moving average of $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.